GlassScriptPhysician profile
William Wong
NPI 1457382772
$11,776.46
in general payments reported to CMS, 2019-2025
27 companies · $699 in 2025
The $699 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,063 · 2020: $3,714 · 2021: $561 · 2022: $921 · 2023: $1,714 · 2024: $1,104 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,509 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,509.26 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $5,321.39 | 2019-2021 | |
| Abbvie INC. | $1,247.14 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $833.17 | 2019-2024 | Eylea, Dupixent, Eylea Hd |
| Leo Pharma INC. | $823.42 | 2021-2025 | Adbry |
| Amgen INC. | $524.56 | 2020-2025 | Otezla, Tepezza, Otezla |
| Arcutis Biotherapeutics, INC. | $349.68 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $340.52 | 2022-2025 | Sotyktu |
| Incyte Corporation | $293.28 | 2022-2024 | Opzelura |
| Ucb, INC. | $267.02 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $244.07 | 2019-2023 | Ilumya, Winlevi |
| Lilly USA, LLC | $231.76 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $203.88 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $143.67 | 2023 | Stellaris |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.58 | 2019-2020 | |
| Glaukos Corporation | $124.97 | 2025 | Idosetr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $108.18 | 2021-2025 | |
| Pfizer INC. | $91.64 | 2019-2023 | |
| Strata Skin Sciences, INC. | $82.45 | 2022-2023 | Xtrac |
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.60 | 2020 | |
| Organon LLC | $58.63 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $51.98 | 2024 | |
| Janssen Biotech, INC. | $48.06 | 2020-2022 | |
| Biotissue Holdings INC. | $34.91 | 2025 | |
| Oyster Point Pharma, INC. | $30.02 | 2024 | Tyrvaya |
| Celgene Corporation | $23.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.